SLSN

Solesence, Inc.

$0.87

-3.41%
SectorConsumer DefensiveIndustryHousehold & Personal ProductsCountryUnited States

Solesence, Inc., a science-driven company, provides engineered materials, formulation development, and commercial manufacturing services in the United States. The company engages in the manufacture and supply of surface engineered zinc oxide and titanium dioxide ingredients. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients; and skin health products, such as sunscreens and daily care products. The company sells products in various markets, including medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications. It serves skin health, beauty, and wellness sectors. The company was formerly known as Nanophase Technologies Corporation and changed its name to Solesence, Inc. in March 2025. Solesence, Inc. was incorporated in 1989 and is headquartered in Romeoville, Illinois.

Source: Yahoo Finance
AI summary

Price & performance

1M+8.3%
3M+7.0%
YTD-40.8%
1Y-77.7%
52-week range—
Beta0.88
Full chart and returns against a benchmark

Q-Score

40/ 100

Quality against peers; 50 is the peer median.

Growth36
Risk35
Performance63
Valuation39
Profitability36
Leverage50
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$62.1M+18.6%
Net income$1.8M-57.7%
Net margin2.9%-5.2 pts
Historical fundamentals

Red flags in filings

3active red flags
Restated financialsAug 21, 2026
Late filing noticeAug 14, 2026
Exchange listing noticeOct 2, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer29%
Regions, segments, customers and suppliers

Valuation

SLSNIndustryP/E—21.88P/S1.113.41EV/EBITDA—17.95P/B4.678.38PEG—0.95
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate